We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ondine Biomedical Inc (OBI) NPV

Sell:5.50p Buy:6.00p 0 Change: 0.50p (8.00%)
Market closed |  Prices as at close on 25 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.50p
Buy:6.00p
Change: 0.50p (8.00%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.50p
Buy:6.00p
Change: 0.50p (8.00%)
Market closed |  Prices as at close on 25 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.

Contact details

Address:
888-1100 Melville St
VANCOUVER
V6E 4A6
Canada
Telephone:
+1 (0604) 6690555
Website:
https://ondinebio.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 25 September 2023 25/09/23
AGM 24 May 2023 24/05/23
Annual report 23 May 2023 23/05/23
Final results 10 May 2023 10/05/23

General stock information

EPIC:
OBI
ISIN:
CA68234M2058
Market cap:
£13.04 million
Shares in issue:
226.75 million
Sector:
No specific Industry
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Nicolas Loebel
    President, Chief Technology Officer, Executive Director
  • Carolyn Cross
    Chief Executive Officer, Executive Director
  • Choo Kwong
    Interim Chief Financial Officer
  • Thomas Dawson
    Senior Vice President - Corporate Development
  • William Kanz
    Senior Vice President, Engineering and Operations
  • Nikita Parkhaev
    Vice President - Finance
  • Roger Andersen
    Vice President - Regulatory, Clinical and Medical Affairs
  • Jason Hickok
    Vice President - Clinical and Medical Affairs
  • Bill Kanz
    Vice President - Engineering
  • Angelika Vance
    Vice President - Corporate Communications

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.